Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Operating Leases (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Operating Leases for 5 consecutive years, with $6.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Leases fell 17.2% year-over-year to $6.5 million, compared with a TTM value of $6.5 million through Dec 2025, down 17.2%, and an annual FY2025 reading of $6.5 million, down 17.2% over the prior year.
  • Operating Leases was $6.5 million for Q4 2025 at Kiniksa Pharmaceuticals International, down from $7.0 million in the prior quarter.
  • Across five years, Operating Leases topped out at $11.3 million in Q2 2023 and bottomed at $1.3 million in Q2 2022.
  • Average Operating Leases over 5 years is $6.1 million, with a median of $6.8 million recorded in 2025.
  • The sharpest move saw Operating Leases plummeted 63.49% in 2022, then skyrocketed 782.86% in 2023.
  • Year by year, Operating Leases stood at $2.7 million in 2021, then dropped by 1.91% to $2.6 million in 2022, then soared by 282.16% to $10.0 million in 2023, then decreased by 21.42% to $7.9 million in 2024, then fell by 17.2% to $6.5 million in 2025.
  • Business Quant data shows Operating Leases for KNSA at $6.5 million in Q4 2025, $7.0 million in Q3 2025, and $7.2 million in Q2 2025.